3.92
price down icon1.75%   -0.07
after-market アフターアワーズ: 3.87 -0.05 -1.28%
loading
前日終値:
$3.99
開ける:
$3.98
24時間の取引高:
90,535
Relative Volume:
0.66
時価総額:
$16.66M
収益:
-
当期純損益:
$-21.21M
株価収益率:
-0.1202
EPS:
-32.6
ネットキャッシュフロー:
$-16.86M
1週間 パフォーマンス:
+7.10%
1か月 パフォーマンス:
-6.22%
6か月 パフォーマンス:
-10.09%
1年 パフォーマンス:
-54.45%
1日の値動き範囲:
Value
$3.86
$4.04
1週間の範囲:
Value
$3.5407
$4.0845
52週間の値動き範囲:
Value
$1.8001
$20.83

Cingulate Inc Stock (CING) Company Profile

Name
名前
Cingulate Inc
Name
セクター
Healthcare (1170)
Name
電話
(913) 942-2300
Name
住所
1901 W. 47TH PLACE, KANSAS CITY
Name
職員
13
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
CING's Discussions on Twitter

CING を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CING
Cingulate Inc
3.92 15.54M 0 -21.21M -16.86M -32.60
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Cingulate Inc Stock (CING) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-10 開始されました ROTH MKM Buy
2023-12-22 ダウングレード Laidlaw Buy → Hold

Cingulate Inc (CING) 最新ニュース

pulisher
May 28, 2025

Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World

May 28, 2025
pulisher
May 27, 2025

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow

May 27, 2025
pulisher
May 27, 2025

CING: Ascendiant Capital Raises Price Target to $61.00 | CING Stock News - GuruFocus

May 27, 2025
pulisher
May 22, 2025

What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World

May 22, 2025
pulisher
May 20, 2025

Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks

May 20, 2025
pulisher
May 20, 2025

Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Trea - GuruFocus

May 20, 2025
pulisher
May 19, 2025

CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks

May 18, 2025
pulisher
May 18, 2025

CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus

May 18, 2025
pulisher
May 16, 2025

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN

May 16, 2025
pulisher
May 15, 2025

CING: First Quarter 2025 Results - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada

May 15, 2025
pulisher
May 15, 2025

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks

May 15, 2025
pulisher
May 14, 2025

Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks

May 14, 2025
pulisher
May 14, 2025

Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Cingulate receives FDA meeting feedback on ADHD drug - Investing.com

May 14, 2025
pulisher
May 14, 2025

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Cingulate Inc. Receives Formal Pre-New Drug Application Meeting Minutes from the U.S. Food and Drug Administration - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Cingulate Inc Terminates Grant Agreement with Foundation - TipRanks

May 14, 2025
pulisher
May 08, 2025

Cingulate Inc. Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - Stock Titan

May 08, 2025
pulisher
May 05, 2025

27,323 Shares in Cingulate Inc. (NASDAQ:CING) Acquired by Geode Capital Management LLC - Defense World

May 05, 2025
pulisher
Apr 30, 2025

Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301 - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

CING Reports Positive Results for CTx-1301 in Food Effect Study - GuruFocus

Apr 30, 2025
pulisher
Apr 29, 2025

Cingulate announces results from high-dose fed/fast study of CTx-1301 - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Cingulate Announces Positive Top-Line Results from - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - The Manila Times

Apr 29, 2025
pulisher
Apr 22, 2025

Cingulate (NASDAQ:CING) Given New $60.00 Price Target at Ascendiant Capital Markets - Defense World

Apr 22, 2025
pulisher
Apr 11, 2025

Analysts’ Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING) - The Globe and Mail

Apr 11, 2025
pulisher
Apr 10, 2025

Cingulate secures $3m to advance once-daily anxiety treatment - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Cingulate wins $3M from private foundation to help develop third time-release drug - The Business Journals

Apr 10, 2025
pulisher
Apr 10, 2025

CING: 2024 Financial and Operational Results - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Cingulate Inc. (NASDAQ:CING) Shares Purchased by Commonwealth Equity Services LLC - Defense World

Apr 10, 2025
pulisher
Apr 09, 2025

Cingulate Inc Secures $3M Grant for Anxiety Drug - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Cingulate Receives $3 Million Grant from Private Foundation - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Revolutionary Once-Daily Anxiety Drug Gets $3M Boost: Targeting $5.5B Market - Stock Titan

Apr 09, 2025
pulisher
Apr 03, 2025

Cingulate moves closer to ADHD drug submission By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301 - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Cingulate moves closer to ADHD drug submission - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301 - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Breakthrough ADHD Treatment Clears Critical FDA Hurdle: Once-Daily Drug Shows Promise - Stock Titan

Apr 03, 2025

Cingulate Inc (CING) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):